MAX BioPharma has been fortunate to receive support from the National Institutes of Health (NIH) for its research and development activities. MAX BioPharma is pleased to announce that its recent set of Phase 2 SBIR grant applications to the NIH for its Bone Program received favorable and fundable scores in 2015. In March 2016, we received our first SBIR Phase 2 award notification, and in September 2016, we received notice that our second SBIR Phase 2 application has also been awarded. The R&D activities supported by these grants allow us to continue our accelerated path to the clinic with promising drug candidates that stimulate bone formation and rebuild bone that has been lost in osteoporotic patients. Such bone anabolic therapies are rare and MAX BioPharma is poised to develop novel bone anabolic agents. We are excited that our efforts will provide patients with osteoporosis new ways to treat their devastating disease that results in bone fractures, morbidity, and mortality.